Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, India.
J Food Biochem. 2021 Apr;45(4):e13684. doi: 10.1111/jfbc.13684. Epub 2021 Mar 12.
Respiratory diseases are the prime cause of death and disability worldwide. The majority of lung-based diseases are resistant to treatment. Hence, research on unique drugs/compounds with a more efficient and minimum side effect for treating lung diseases is urgent. Punica granatum L (pomegranate) fruit has been used in the prevention and treatment of various respiratory disorders in recent times. In vivo and in vitro studies have demonstrated that pomegranate fruit, as well as its juice, extract, peel powder, and oil, exert anti-proliferative, anti-oxidant, anti-microbial, anti-inflammatory, anti-cancer, and anti-tumorigenic properties by attenuating various respiratory conditions such as asthma, lung fibrosis, lung cancer, chronic obstructive pulmonary disease (COPD), and alveolar inflammation via modulating various signaling pathways. The current review summarizes the potential properties and medical benefits of pomegranate against different lung-based diseases, also highlighting its possible role in the lung fibrinolytic system. The available data suggest that pomegranate is effective in controlling the disease progressions and could be a potential therapeutic target benefiting human health status. Furthermore, this review also outlines the preclinical and clinical studies highlighting the role of pomegranate in lung diseases further evoking future studies to investigate the effect of intake of this anti-oxidant fruit in larger and well-defined human clinical trials. PRACTICAL APPLICATIONS: This review outlines the putative pharmacologic benefits of P. granatum L (pomegranate) in treating various chronic lung-based diseases such as lung cancer, COPD, ARDS, asthma, lung fibrosis, and cystic fibrosis. This review also highlights the possible inhibitory role of P. granatum L (pomegranate) in the lung fibrinolytic system triggering the fibrinolytic markers. This review summarizes the preclinical and clinical studies using in vitro, in vivo, and human models highlighting the potential role of P. granatum L (pomegranate) in lung diseases. This review evokes future research to investigate the effect of intake of pomegranate fruit in well-defined human clinical trials.
呼吸系统疾病是全球范围内死亡和残疾的主要原因。大多数肺部疾病对治疗具有耐药性。因此,迫切需要研究具有更高效率和最小副作用的独特药物/化合物,用于治疗肺部疾病。近年来,石榴(pomegranate)果实已被用于预防和治疗各种呼吸系统疾病。体内和体外研究表明,石榴果实及其果汁、提取物、果皮粉和油,通过调节各种信号通路,对哮喘、肺纤维化、肺癌、慢性阻塞性肺疾病(COPD)和肺泡炎症等各种呼吸系统疾病具有抗增殖、抗氧化、抗菌、抗炎、抗癌和抗肿瘤特性。本综述总结了石榴对不同肺部疾病的潜在特性和医学益处,同时强调了其在肺部纤维蛋白溶解系统中的可能作用。现有数据表明,石榴在控制疾病进展方面是有效的,并且可能是有益于人类健康状况的潜在治疗靶点。此外,本综述还概述了强调石榴在肺部疾病中作用的临床前和临床研究,进一步呼吁未来的研究调查摄入这种抗氧化水果对更大和定义明确的人体临床试验的影响。
本综述概述了石榴(pomegranate)在治疗各种慢性肺部疾病(如肺癌、COPD、ARDS、哮喘、肺纤维化和囊性纤维化)中的潜在药理益处。本综述还强调了石榴(pomegranate)在肺部纤维蛋白溶解系统中可能具有抑制作用,触发纤维蛋白溶解标志物。本综述总结了使用体外、体内和人体模型的临床前和临床研究,强调了石榴(pomegranate)在肺部疾病中的潜在作用。本综述呼吁未来的研究调查摄入石榴在明确人体临床试验中的效果。